Full Text CA-95-012


NIH GUIDE, Volume 24, Number 15, April 28, 1995

RFA:  CA-95-012

P.T. 34

  Treatment, Medical+ 

National Cancer Institute

Letter of Intent Receipt Date:  September 1, 1995
Application Receipt Date:  October 20, 1995


The Cancer Therapy Evaluation Program (CTEP) and the Biological
Response Modifiers Program (BRMP), Division of Cancer Treatment
(DCT), National Cancer Institute (NCI) invites research grant
applications for the conduct of therapeutic clinical trials research
employing new agents, concepts, or strategies for the treatment of
cancer.  This initiative is aimed at encouraging new clinical
investigators who have not previously had independent grant funding
to submit research applications in this area of research.


The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas. This Request
for Applications (RFA), Investigator Grants for Clinical Cancer
Therapy Research, is related to the priority area of cancer.
Potential applicants may obtain a copy of "Healthy People 2000" (Full
Report:  Stock No. 017-001-00474-0 or Summary Report:  Stock No.
017-001-00473-1) through the Superintendent of Documents, Government
Printing Office, Washington, DC 20402-9325 (telephone 202/783-3238).


Applications may be submitted by domestic non-profit and for-profit
organizations, public and private, such as universities, colleges,
hospitals, laboratories, units of State or local governments, and
eligible agencies of the Federal government.  Applications from
minority and women investigators are encouraged.

An important principle to remember is that the more extensive the
prior independent research experiences, regardless of funding
sources, the greater likelihood there will be diminished priority for


This RFA will use the National Institutes of Health (NIH) individual
research grant (R01) as its funding mechanism.  Responsibility for
the planning, direction, and execution of the proposed project will
be solely that of the applicant.  The total project period for
applications submitted in response to the present RFA may not exceed
four years.

The direct cost for the four year period may not exceed $500,000.
The direct cost in any budget period may not exceed $150,000.  The
anticipated award date is July 1996.

Awards and level of support depend on receipt of a sufficient number
of applications of high scientific merit.  Although this program is
provided for in the financial plans of the NCI, the award of grants
pursuant to this RFA is contingent upon the continuing availability
of funds for this purpose.

This RFA is a one-time solicitation for new applications for award in
FY 96.  NCI encourages investigators who responded to the previous
solicitation (RFA CA-94-014) to resubmit.  The NCI has plans to re-
issue this RFA for funding in 1997.  Future unsolicited competing
continuation applications will compete with all
investigator-initiated applications and be reviewed according to the
customary peer review procedures.


Approximately $2,000,000 in total costs per year for each of four
years will be committed to fund applications submitted in response to
this RFA.  It is anticipated that ten new individual awards will be



In the past year, a number of groups have expressed concern over the
declining number of clinical investigators entering and remaining in
academic research.  Clinical investigators are a critical component
in translating new therapeutic agents and modalities from the
laboratory into the clinic.  They must maintain a broad perspective
and knowledge concerning clinical and basic sciences, while
developing new cancer therapies that are hypothesis driven.  They are
highly interactive with basic and clinical researchers in related
disciplines.  This translational clinician is considered distinct
from the clinician who also has a PhD or equivalent training and
concentrates on basic research or the clinician who participates in
cancer research solely by entering patients on clinical trials.

The Clinical Investigations Task Force of the National Cancer
Advisory Board and a sub-committee of the American Association of
Clinical Oncology (ASCO) have both been addressing the problem of the
decreasing number of academic clinical investigators.  One of the
problems identified is the lack of suitable mechanisms for the
training and funding of clinical oriented investigators involved in
translating basic research into new cancer treatments.  The
traditional grants mechanisms (R01, R29) are under-utilized and often
do not fit the needs of young clinical investigators for the support
of clinical trials research.  The R29 grant mechanism requires the
investigator to devote at least 50 percent effort to a five year
project and the yearly budget is limited to approximately $70,000.
Most clinicians have major clinical and teaching responsibilities and
it is impossible to support both the clinical and laboratory
components needed within the budget limitations of an R29 grant.  New
clinical investigators often do not have the publication or research
track record to be competitive for R01 grant support.  Thus, very few
clinical trial research applications are submitted by new clinical
investigators.  DCT would like to reverse this trend and encourage
new clinical investigators, who have not previously received R01 or
R29 grant support, to submit grant applications for the conduct of
translational clinical trials research.

Project Description

The Cancer Therapy Evaluations Program and the Biological Response
Modifiers Program encourage qualified clinical investigators to
develop R01 grant applications for the conduct of cancer clinical
trials research on new therapeutic agents and modalities.  Grant
applications must include clinical trials involving human subjects
and designed to ultimately improve cancer survival.  The clinical
trials must have a strong rationale and be based upon preclinical
data, preferably generated by the applicant or collaborators, that
support the underlying hypotheses.  New clinical therapeutic trials
employing drugs (including differentiating agents), biologics
(including cytokines, antibodies), vaccine strategies, radiation, or
surgery whether used as a single agent/modality or in combination are
appropriate.  Investigators are urged especially to address the more
difficult therapeutic challenges, including the most common
malignancies (e.g., breast, ovarian, prostrate, lung).

Laboratory studies to monitor patients or to study the mechanism of
antitumor effect and resistance should be included.  The laboratory
studies should be in support of the clinical trial, such that their
conduct leads to a greater understanding of the relationship of the
therapy and biological changes in the patient or the mechanism of
action of an anti-tumor response.  Laboratory studies would include
pharmacokinetic studies of cytotoxic, immune-modulating,
differentiation-inducing, and/or targeted therapeutic agents or
relevant pharmacodynamic correlative studies.  Measurement of
particular biological responses would also be desirable particularly
when this information would be relevant to the interpretation of the
success or failure of the therapy in individual patients on the
clinical trial.

It is expected that a significant level of effort, at least 25
percent, will be committed to the research project by the Principle
Investigator.  Applicants from institutions that have a General
Clinical Research Center (GCRC) funded by the NIH National Center for
Research Resources may wish to identify the GCRC as a resource for
conducting the proposed research.  If so, a letter of agreement from
either the GCRC program director or Principal Investigator must be
included with the application.


It is the policy of the NIH that women and members of minority groups
and their subpopulations must be included in all NIH supported
biomedical and behavioral research projects involving human subjects,
unless a clear and compelling rationale and justification is provided
that inclusion is inappropriate with respect to the health of the
subjects or the purpose of the research.  This new policy results
from the NIH Revitalization Act of 1993 (Section 4928 of Public Law
103-43) and supersedes and strengthens the previous policies
(Concerning the Inclusion of Women in Study Populations, and
Concerning the Inclusion of Minorities in Study Populations), which
have been in effect since 1990.  The new policy contains some
provisions that are substantially different from the 1990 policies.

All investigators proposing research involving human subjects should
read the "NIH Guidelines for Inclusion of Women and Minorities as
Subjects in Clinical Research," which have been published in the
Federal Register of March 28, 1994 (FR 59 14508-14513) and reprinted
in the NIH guide for Grants and Contracts, Volume 23, Number 11,
March 18, 1994.

Investigators also may obtain copies of the policy from the program
staff listed under INQUIRIES.  Program staff may also provide
additional relevant information concerning the policy.


Prospective applicants are asked to submit, by September 1, 1995, a
letter of intent that includes a descriptive title of the proposed
research, the name, address, and telephone number of the Principal
Investigator, the identities of other key personnel and participating
institutions, and the number and title of the RFA in response to
which the application may be submitted.

Although a letter of intent is not required, is not binding, and does
not enter into the review of subsequent applications, the information
is helpful in planning for the review of applications.  It allows NCI
staff to estimate the potential review workload and to avoid conflict
of interest in the review.

The letter of intent is be sent to:

Ms. Diane Bronzert
Division of Cancer Treatment
National Cancer Institute
Executive Plaza North, Room 734
Bethesda, MD  20892
Telephone:  (301) 496-8866
FAX:  (301) 480-4663


The research grant application form PHS 398, (rev. 9/91) is to be
used in applying for this RFA.  These forms are available at most
institutional offices of sponsored research; from the Office of
Grants Information, Division of Research Grants, National Institutes
of Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone
(301) 710-0267; and from the NCI program staff listed under
INQUIRIES.  The RFA label available in the PHS 398 application form
must be affixed to the bottom of the face page.  Failure to use this
label could result in delayed processing of the application such that
it may not reach the review committee in time for review.  In
addition, the RFA number and title must be typed on line 2a of the
face page of the application form and the YES box must be marked.

Submit a signed, typewritten original of the application, including
the Checklist, and three signed, exact photocopies, in one package

Division of Research Grants
National Institutes of Health
6701 Rockledge Drive, Room 1040  MSC 7710
Bethesda, MD  20892-7710
Bethesda, MD  20817 (for express/courier service)

At the time of submission, two additional copies of the application
must also be sent to:

Ms. Toby Friedberg
Division of Extramural Activities
National Cancer Institute
Executive Plaza North, Room 636
6130 Executive Boulevard
Bethesda, MD  20892
Bethesda, MD  20852 (for express mail)

Applications must be received by October 20, 1995.  If an application
is received after that date, it will be returned.  The Division of
Research Grants (DRG) will not accept any application in response to
this RFA that is essentially the same as one currently pending
initial review, unless the applicant withdraws the pending
application.  The DRG will not accept any application that is
essentially the same as one already reviewed.  This does not preclude
the submission of substantial revisions of applications already
reviewed, but such applications must include an introduction
addressing the previous critique.

B.  Special Instructions for the Completion of the PHS 398

NIH has recently been designated a "re-invention laboratory" by the
Public Health Service.  One component of our efforts to streamline
NIH operations is to simplify the grant application and review

Therefore, an experiment is being conducted to determine ways to
reduce the administrative burden in applying for an NIH grant without
compromising those elements needed by the initial scientific peer
review group to assess the scientific merit of the application and
the reasonableness of the proposed budget.

In responding to the RFA, the following are specific instructions for
sections of the PHS 398 application form (rev. 9/91) that should be
completed differently from usual.  Some sections are modified and
others in the application do not need to be completed for the
submission of the application but WILL be requested if your
application receives a priority score in the fundable range.  For all
other items in the application, follow the usual instructions on
pages 9-32 of the PHS 398 booklet.

FACE PAGE (Form AA) - The title and number of the RFA must be typed
in line 2a.  Failure to do so could result in delayed processing of
your application such that it may not reach the review committee in
time for review.

Item 10, INVENTIONS AND PATENTS - Do not complete.  See Specific
Instructions - Appendix for Instructions.

Enter direct costs only for the following:

o  Personnel, Patient Care Costs, Alterations-Renovations - Complete
these sections as instructed in the PHS 398 booklet.

o  Consultant Costs - Itemize only if proposed consultant costs
exceed $10,000 or if a consultant is identified as key personnel.

o  Equipment - Itemize only individual equipment items in excess of

o  Supplies - Itemize (a) all animal costs and (b) any individual
supply item which costs more than $10,000. If animals are involved,
state their unit purchase and care costs.  Enter total animal costs
and supply costs on separate lines.

o  Travel and Other Expenses - Itemize any expense category that
exceeds $5,000.

complete this page.  Unless you are requesting unusual increases or
decreases in future years, they will be automatically escalated on
the direct costs proposed for the first year (minus one time costs
for equipment) by four percent.

Form FF - Page 6 - BIOGRAPHICAL SKETCH - For each KEY person only,
provide a two-page biographical sketch.

Name, Position Title, Education - Complete these sections as
instructed in the PHS 398 booklet.

Research and Professional Experience - Identify your research
background and experience relevant to the research proposed.
Specifically, provide:

o  A list of previous research positions that are felt to be of
significance or relevance for the review of the proposed research;

o  Complete references, titles, and authors on all peer-reviewed
publications representative of your research career or pertinent to
the research proposed;

o  The title and funding source of all active research grants or
contracts on which you are principal investigator, co-investigator,
or project leader.  Indicate current percent effort for each award.

o  The title and length of service on any peer review group, council,
or program advisory committee.

Form GG - Page 7 - OTHER SUPPORT - Do not complete.  Updated
information will be requested by NCI staff from only those applicants
being considered for funding.

Form HH - Page 8 - RESOURCES AND ENVIRONMENT - Complete this section
as requested in the PHS 398 form.

Applications in response to this RFA should be concise and shorter
than regular grant applications.  Items 1-4 may not exceed 20 pages
in total.

Item 1 - Specific Aims - In one page or less, list in priority order,
the broad, long-range objectives. Describe concisely and
realistically the hypothesis to be tested and what the specific
research described in this application is intended to accomplish.

Item 2 - Background and Significance - In two to three pages, use
this section to describe (a) how the proposed research will
contribute to meeting the goals and objectives of the RFA; and, (b)
explain the rationale for the selection of the general methods and
approaches proposed to accomplish your specific aims.

Items 3-4 - Progress Report/Preliminary Studies, Research Design and
Methods - In seventeen pages or less, complete as instructed on pages
20-21 of the PHS 398 booklet with the modification that the clinical
protocol(s) and up to six publications, manuscripts submitted or
accepted for publication, patents, or invention reports can be
included in the Appendix (see below).

Investigator may use this section to address the following:

o  preliminary studies pertinent to the application;

o  rationale and hypothesis for the clinical trial and laboratory

o  general methods that will be utilized; provide specific details
for those techniques which are unique or where a significant
departure from a generally accepted technique is important for
reviewers to know;

o  outcome measures that will be used to assess the success or
failure of each set of experiments (include statistical analyses for
laboratory and clinical studies);

o  plans for the rigorous data management and verification of
research data;

o  potential pitfalls in the experimental design and alternative
studies that will be done if the proposed experiments fail.

Items 5-6 - Human Subjects, Vertebrate Animals - Complete as
described on pages 22-23.  State clearly the plans for early
detection of and protection against adverse effects on human
subjects.  Documentation for the composition of the proposed study
population in terms of gender and racial/ethnic group together with a
rationale for its choice must be included in the Human Subjects

Item 7 - Consultants/Collaborators - Biographical sketches should
conform to the brief format described previously for Form FF.

Item 8 - Consortium, Contractual Arrangements - In one page or less,
provide a brief explanation of the programmatic fiscal and
administrative arrangements made with collaborating organizations.

Item 9 - Literature Cited - In five pages or less, give full
literature citations including the title of the article.

SPECIFIC INSTRUCTIONS - APPENDIX (Page 24) - Up to ten publications,
manuscripts submitted or accepted for publication, patents, and
invention reports may be provided.  Clinical protocol(s) must be
included in this section.  Other than this change, complete as

Questions regarding these instructions may be directed to the program
staff listed under INQUIRIES.


Upon receipt, applications will be reviewed by the Division of
Research Grants (DRG) for completeness and by the NCI for
responsiveness.  Incomplete applications will be returned to the
applicant without further consideration.  If the application is not
responsive to the RFA, NCI staff may contact the applicant to
determine whether to return the application to the applicant or
submit it for review in competition with unsolicited applications at
the next review cycle.

Applications that are complete and responsive to the Request for
Applications will be evaluated for scientific and technical merit by
an appropriate peer review group convened by the NCI in accordance
with the review criteria stated below.  As part of the initial merit
review, all applications will receive a written critique and may
undergo a process in which only those applications deemed to have the
highest scientific merit will be discussed, assigned a priority
score, and receive a second level review by the National Cancer
Advisory Board.

The review group will assess the scientific merit of the studies
using the following review criteria:

1.  Importance, timeliness, and clinical merit of the clinical

2.  Quality of data supporting the proposed clinical trial.

3.  Scientific and technical merit of the proposed laboratory

4.  Relevance of the proposed laboratory studies to the clinical

5.  Research training and clinical qualifications of the Principal
Investigator and staff in the area of the proposed research.

6.  Availability and quality of the resources necessary to perform

7.  Quality of data verification and management plans and statistical

The initial review group will critically examine the submitted budget
and will recommend an appropriate budget and period of support for
each approved application.  They will also examine the provisions for
the protection of human and animal subjects, the safety of the
research environment, and conformance with the NIH Guidelines for the
Inclusion of Women and Minorities as Subjects in Clinical Research.


Applications considered by the National Cancer Advisory Board will be
considered for award based upon (a) scientific and technical merit;
(b) availability of funds; and (c) programmatic priorities.
Preference will also be given to clinical investigators who are new
to this research area.

Letter of Intent Receipt Date:             September 1, 1995
Application Receipt Date:                  October 20, 1995 Review by
National Cancer Advisory Board:  May 1996
Anticipated Award Date:                    July 1996


Written and telephone inquiries concerning the objectives and scope
of this RFA and inquiries about whether or not specific proposed
research would be responsive are strongly encouraged.  The program
staff welcome the opportunity to clarify any issues or questions from
potential applicants.

Direct inquiries regarding general programmatic issues and
chemotherapy agents to:

Ms. Diane Bronzert
Division of Cancer Treatment
National Cancer Institute
Executive Plaza North, Room 734
6130 Executive Boulevard MSC 7432
Bethesda, MD  20892-7432
Telephone:  (301) 496-8866
FAX:  (301) 480-4663

Direct inquiries regarding programmatic issues using biologics to:

Dr. Toby Hecht
Division of Cancer Treatment
National Cancer Institute
FCRDC 1052, Room 247
Bethesda, MD  20892
Telephone:  (301) 846-1098
FAX:  (301) 846-5429

Direct inquiries regarding fiscal matters to:

Ms. Eileen M. Natoli
Grants Administration Branch
National Cancer Institute
Executive Plaza South, Room 243
6120 Executive Boulevard MSC 7150
Bethesda, MD  20892-7150
Telephone:  (301) 496-7800, ext. 256
FAX:  (301) 496-8601


This program is described in the Catalog of Federal Domestic
Assistance No 93.395, Cancer Treatment Research.  Awards are made
under the authorization of the Public Health Service Act, Title IV,
Part A (Public Law 78-410, as amended, Public Law 99-158, 42 USC 241
and 285) and administered under HHS grants policies.  This program is
not subject to the intergovernmental review requirements of Executive
Order 12372 or Health Systems Agency review.

The PHS strongly encourages all grant and contract recipients to
provide a smoke-free workplace and promote the non-use of all tobacco
products.  In addition, Public Law 103-227, the Pro-Children Act of
1994, prohibits smoking in certain facilities (or in some cases, any
portion of a facility) in which regular or routing education,
library, day care, health care or early childhood development
services are provided to children.  This is consistent with the phs
mission to protect and advance the physical and mental health of the
american people.


Return to RFAs Index

Return to NIH Guide Main Index

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.